Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu-177 XT033
- Development stage
- Phase 2
- Lead developer
- Sinotau Pharmaceutical Group
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
Lutetium Lu-177 XT033 is a radioligand therapy (RLT) drug designed for the treatment of metastatic prostate cancer that expresses prostate specific membrane antigen (PSMA)[1][4]. It consists of a peptide-based carrier with high affinity for PSMA, enabling selective delivery of the radioactive isotope lutetium-177 to prostate cancer cells[4]. A unique feature is its inclusion of an Evans blue fragment, which prolongs circulation time and enhances tumor uptake by increasing metabolic stability. The therapeutic effect is mediated by beta emission from lutetium-177, delivering targeted radiation to eradicate cancer cells while minimizing damage to surrounding healthy tissue[4]. Lutetium Lu-177 XT033 has demonstrated promising preclinical efficacy in tumor regression and survival extension in animal models[4].
- Other names
- [177Lu]Lu-XT033 injection
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on lutetium Lu-177 XT033.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu-177 XT033.